Horizon Stock Breaks Out With Earnings Windfall Expected In Second Quarter

Horizon Therapeutics (HZNP) is expected to double its second-quarter earnings in August, leading HZNP stock to run up and break out on Thursday.


The biotech company is known for gout treatment Krystexxa and its new medicine, a treatment for thyroid eye disease called Tepezza. The Covid pandemic threw a wrench into first-quarter Tepezza sales as a short-term supply issue disrupted manufacturing.

Now, expectations are for Horizon to capture nearly 50% sales growth in the second quarter and a triple-digit increase in earnings.

Ahead of those bullish forecasts, HZNP stock broke out of a flat base with a buy point at 97.46 on‘s weekly chart. In afternoon trading on the stock market today, HZNP stock rose 3.9% near 99.90.

HZNP Stock: Earnings Appear Bullish

For the second quarter, HZNP stock analysts polled by FactSet expect Horizon to report adjusted earnings of 87 cents per share and $691 million in sales. Earnings would soar nearly 118%. Sales would jump more than 49% on a year-over-year basis.

Rare disease treatments known as orphan drugs — which includes Krystexxa and Tepezza — would account for close to 61% of total sales.

Despite the slow Tepezza quarter in which sales plunged 91%, Horizon raised its guidance for the full year. The company guided to $2.75 billion to $2.85 billion in full-year sales, up from its prior estimate for $2.7 billion to $2.8 billion.

The guidance assumes full-year Tepezza sales of greater than $1.28 billion and for Krystexxa sales to top $500 million.

Shares Rally Year To Date

Horizon is on deck to report its second-quarter earnings on Aug. 4.

HZNP stock has climbed more than 36% on a year-to-date basis, as of Thursday afternoon.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Abbott Hits The Skids As Covid Testing Demand Falls Off Despite Quarterly Beat

Biogen’s Marquee Alzheimer’s Drug Launches, But Sales Fall Slightly Short

IBD’s Leaderboard Is Turning 10! Celebrate With Us

Learn How To Time The Market With IBD’s ETF Market Strategy

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button